2025-08-11
The Swedish government launches SweTrial, a national partnership to increase clinical trials and strengthen Sweden’s life science competitiveness.
The Swedish government has initiated SweTrial, a national partnership aimed at strengthening Sweden’s position in clinical trials and the life science sector. This initiative targets the recent decline in clinical trials in Sweden and aims to improve competitiveness in healthcare, research, and industry.
SweTrial will serve as a central coordination hub where healthcare, academia, industry, and government agencies collaborate closely. The Swedish Medical Products Agency (Läkemedelsverket) has been tasked with establishing and managing SweTrial, including setting formal agreements among all involved parties.
According to Ann Lindberg, Director-General of Läkemedelsverket, “We look forward to establishing the SweTrial secretariat. Our agency’s extensive experience in regulatory affairs and clinical trials will be a valuable contribution to this partnership.”
To encourage more companies to conduct clinical trials in Sweden, the government has also launched a review to simplify regulations and reduce barriers. SweTrial will help coordinate the allocation of public funding transparently and efficiently, ensuring fair distribution to support high-quality clinical research.
Peter Asplund, project leader at Läkemedelsverket, highlights the inclusive approach: “From the start, collaboration has been key. We have engaged representatives from healthcare, industry, academia, authorities, and patient groups to develop solutions that benefit all.”
SweTrial will be led by a council representing all partners, ensuring accountability and shared responsibility. The council will guide the initiative’s priorities and monitor progress continuously. A dedicated secretariat within Läkemedelsverket will handle coordination and administration.
This governance model aims to create an effective, open, and participatory framework that supports innovation and patient access to cutting-edge treatments.
In addition to SweTrial’s coordination role, Läkemedelsverket has been tasked with providing SEK 10 million in funding to Biobank Sweden. This investment will enhance biobank infrastructure, crucial for handling samples and supporting clinical trials at a high standard.
Robust biobank systems are vital for modern clinical research and help ensure Sweden remains competitive internationally.
SweTrial is a key element in Sweden’s broader life science strategy, designed to attract more clinical research and foster innovation. By bringing together all stakeholders and streamlining processes, SweTrial will help deliver better treatments to patients faster and strengthen Sweden’s reputation as a leading life science nation.